The Effectiveness of Colistin/Rifampin Compared to Colistin/Meropenem in the Treatment of Ventilator-associated Pneumonia Caused by Carbapenem-resistant Acinetobacter baumannii: A Randomized Controlled Clinical Trial
Abstract
Objective: Treating ventilator-associated pneumonia (VAP) caused by carbapenem-resistant Acinetobacter baumannii (CRAB) is still a significant challenge. This study evaluated the effectiveness of the colistin/rifampin regimen compared to the usual colistin/meropenem regimen in treating patients with VAP caused by CRAB. Methods: In a randomized controlled clinical trial, the patients with CRAB-related VAP were randomly assigned to experimental (n = 21) and control (n = 24) groups. The first group received colistin 4.5 MIU IV infusion every 12 h and rifampin 300 mg PO every 12 h, and the second group received colistin with the same dose and meropenem 2 g IV every 8 h for 10 days. The clinical response (complete response, partial response, or treatment failure) and mortality rate at the end of the intervention were recorded and compared between the two groups. Findings: The complete response rate was higher (n = 8; 66.70%), and the failure rate was lower (n = 4; 26.70%) in the experimental group than in the control group (n = 4; 33.30%, and n = 11; 73.30%, respectively), but the differences were not statistically significant. The mortality rate was three patients in both experimental (14.28%) and control (12.50%) groups; however, the difference was not statistically significant (P = 0.860; odds ratio: 1.143, 95% confidence interval: 0.258–5.067). Conclusion: The colistin/rifampin combination can be considered an alternative regimen to colistin/meropenem in the treatment of VAP…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 24 participants or records.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Levofloxacin-Induced Tendon Rupture: A Case Report and Review of the Literature
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- Neuroprotective Effects of Epicatechin against Oxidative Stress-Induced Cognitive Impairment: A Systematic Review and Meta-Analysis
- Quality evaluation and in vitro interaction studies between levofloxacin 250mg and diclofenac sodium 50mg tablets
- Molecular Epidemiology of mcr-1 -Positive Polymyxin B-Resistant Escherichia coli Producing Extended-Spectrum β-Lactamase (ESBL) in a Tertiary Hospital in Shandong, China
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.